Table 3.
Multivariate survival analyses in relation to PFS and OS in NSCLC patients
| Variables | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI lower | 95% CI upper | P | HR | 95% CI lower | 95% CI upper | P | |
| Gender | ||||||||
| Female | 1 | 1 | ||||||
| Male | 1.148 | 0.757 | 1.740 | 0.517 | 1.029 | 0.663 | 1.597 | 0.900 |
| Age (years) | ||||||||
| <45 | 1 | 1 | ||||||
| 45–65 | 0.955 | 0.549 | 1.659 | 0.870 | 0.708 | 0.399 | 1.258 | 0.239 |
| 65–80 | 1.222 | 0.701 | 2.127 | 0.479 | 0.872 | 0.484 | 1.569 | 0.647 |
| ≥80 | 2.237 | 0.949 | 5.275 | 0.066 | 1.552 | 0.601 | 4.009 | 0.364 |
| Smoking | ||||||||
| Non-smoker | 1 | |||||||
| Smoker | 1.111 | 0.757 | 1.630 | 0.592 | 1.298 | .845 | 1.996 | 0.234 |
| Tumor stage | ||||||||
| I | 1 | 1 | ||||||
| II | 1.002 | 0.631 | 1.592 | 0.992 | 1.004 | 0.621 | 1.623 | 0.986 |
| III | 1.497 | 0.869 | 2.581 | 0.146 | 1.540 | 0.843 | 2.815 | 0.160 |
| IV | 1.140 | 0.724 | 1.795 | 0.571 | 1.028 | 0.640 | 1.650 | 0.910 |
| Node stage | ||||||||
| N0 | 1 | 1 | ||||||
| N1 | 1.519 | 0.831 | 2.776 | 0.174 | 1.549 | 0.804 | 2.986 | 0.191 |
| N2 | 1.280 | 0.797 | 2.056 | 0.308 | 1.108 | 0.667 | 1.842 | 0.691 |
| N3 | 1.410 | 0.836 | 2.378 | 0.198 | 0.898 | 0.510 | 1.582 | 0.711 |
| Metastasis stage | ||||||||
| M0 | 1 | 1 | ||||||
| M1a | 1.882 | 1.232 | 2.874 | 0.003 | 1.841 | 1.148 | 2.953 | 0.011 |
| M1b | 2.321 | 1.602 | 3.362 | <0.001 | 2.264 | 1.477 | 3.473 | <0.001 |
| Neutrophil (cells/ml) | ||||||||
| ≤3.41 × 109 | 1 | 1 | ||||||
| >3.41 × 109 | 1.160 | 0.753 | 1.788 | 0.501 | 1.020 | 0.655 | 1.586 | 0.931 |
| NLR | ||||||||
| ≤2.68 | 1 | 1 | ||||||
| >2.68 | 1.535 | 1.064 | 2.212 | 0.022 | 1.778 | 1.157 | 2.732 | 0.009 |
| PLR | ||||||||
| ≤119.50 | 1 | 1 | ||||||
| >119.50 | 1.189 | 0.852 | 1.658 | 0.309 | 1.079 | 0.729 | 1.596 | 0.705 |
| CRP (mg/L) | ||||||||
| ≤10.4 | 1 | 1 | ||||||
| >10.4 | 1.766 | 1.264 | 2.467 | 0.001 | 1.774 | 1.270 | 2.477 | 0.001 |
AC, adenocarcinoma; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; PLR, platelet to lymphocyte ratio; SCC, squamous carcinoma; TNM, tumor node metastasis.